Squarepoint
NYMX

Squarepoint’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Squarepoint’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-11,816
Closed -$29K – 3773
2020
Q4 		$29K Sell
11,816
-6,299
-35% -$13.9K ﹤0.01% 2830
2020
Q3 		$45K Sell
18,115
-44,099
-71% -$128K ﹤0.01% 2378
2020
Q2 		$221K Buy
+62,214
New +$197K ﹤0.01% 1780
2018
Q1 		– Sell
-10,194
Closed -$34K – 2278
2017
Q4 		$34K Buy
+10,194
New +$37.2K ﹤0.01% 2033

Other funds holding NYMX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Squarepoint's NYMX Position: Q1 2021 in Review

Squarepoint sold out of Nymox Pharmaceutical Corp (NYMX) in Q1 2021, closing a stake of 11,816 shares — an estimated $29K sold.

Squarepoint first reported a position in NYMX in Q4 2017 and held it in 4 quarters. The position peaked at $221K in Q2 2020. 59 funds tracked by Wall St. Rank hold NYMX as of Q1 2021.

  • Squarepoint reported no remaining Nymox Pharmaceutical Corp position as of Q1 2021 after selling out during the quarter.
  • Squarepoint sold 11,816 Nymox Pharmaceutical Corp shares in Q1 2021, an estimated $29K.
  • Squarepoint first reported a position in Nymox Pharmaceutical Corp in Q4 2017 and held it in 4 quarters.
  • Squarepoint's Nymox Pharmaceutical Corp position peaked at $221K in Q2 2020.
  • 59 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q1 2021.

Based on Squarepoint's 13F filing for Q1 2021, filed 17 May 2021.